Testicular Cancer Summit Honorary Speaker - Dr. Lawrence Einhorn
Dr. Einhorn, or "Dr E" as he's affectionately referred to within the TC community, is a man who needs no introduction. Many of us would not even be here were it not for Dr. Einhorn's pioneering work in the 1970's that led to a once in a generation leap in the oncology field, and the cures for many cancers including Testicular Cancer.
Dr. Einhorn, or "Dr E" as he's affectionately referred to within the TC community, is a man who needs no introduction. Many of us would not even be here were it not for Dr. Einhorn's pioneering work in the 1970's that led to a once in a generation leap in the oncology field, and the cures for many cancers including Testicular Cancer! It was a great honor to be the first Testicular Cancer centric group to host the man who invented the cure for this disease! Why hadn't this been done before? Well it has now.
"Lawrence Einhorn, MD, has been on the IU School of Medicine Department of Medicine faculty since 1973. His field of expertise includes clinical trials and supportive care, with focus in the areas of lung and testicular cancers. Dr. Einhorn has also been involved in the clinical development of new drug therapies. Studies chaired by Dr. Einhorn at IU School of Medicine in the area of testicular cancer led to the FDA approval of cisplatin, etoposide and ifosfamide. In addition, his groups conducted the pivotal studies that led to the approval of both gemcitabine and pemetrexed in non-small cell lung cancer.
A major current area of focus for Dr. Einhorn is supportive care and survivorship, especially as it applies to patients who are cured with platinum-based chemotherapy for testicular cancer. He has been a long-standing member of the Multi-National Association for Supportive Care in Cancer (MASCC).
Dr. Einhorn's clinical interests include solid tumor oncology, specifically within the fields of genitourinary and lung cancers. His legacy will forever be linked with revolutionizing testicular cancer treatment. Prior to Dr. Einhorn's research in the area of platinum combination chemotherapy in patients with metastatic testicular cancer, the survival rate of the disease was approximately 10 percent. Now, due to Dr. Einhorn's monumental findings, the current survival rate for metastatic testicular cancer is at 80 percent.
Dr. Einhorn rose to even greater prominence when he used his novel treatment paradigm to treat Lance Armstrong, cancer advocate and seven-time winner of the Tour de France. With Dr. Einhorn's treatment, Armstrong survived stage 3 testicular cancer that initially presented with abdominal, brain and lung metastases. Like Armstrong, Einhorn remains dedicated to raising cancer awareness. He was appointe the first Lance Armstrong Foundation professor of oncology in 2006."
Testicular Cancer Summit Panelist - Dr. Clint Cary
At the Testicular Cancer Summit, we will have not one but two amazing testicular cancer doctors on hand to answer your questions in two hour-long "Ask the Oncologists Anything Q&A" breakout sessions, Dr Phil Pierorazio of Johns Hopkins Medicine, and Dr Clint Cary of Indiana University! You've already been introduced to Dr Pierorazio, but here's a bit about Dr Clint Cary!
At the Testicular Cancer Summit, we will have not one but two amazing testicular cancer doctors on hand to answer your questions in two hour-long "Ask the Oncologists Anything Q&A" breakout sessions, Dr Phil Pierorazio of Johns Hopkins Medicine, and Dr Clint Cary of Indiana University! You've already been introduced to Dr Pierorazio, but here's a bit about Dr Clint Cary!
Dr. Cary completed his urology residency at Indiana University and then went on to complete a two year urologic oncology fellowship at the University of California, San Francisco. In addition to his fellowship, he completed a Master of Public Health Degree from U.C. Berkeley with a concentration in epidemiology. His clinical interest is in urologic oncology with a focus on the surgical management of advanced testicular cancer and bladder cancer. His research efforts focus on health services and outcomes research in testis and bladder cancer.
How many times have you been in your doctor's office and have felt so rushed, or like you didn't have enough time, or forgot what you were going to ask, and then you're left kicking yourself and wondering for the next month or until your next appointment? And then the same thing happens all over again!! It happens to all of us! These Oncology Q&A panel discussions will be the perfect opportunity for so many of us to sit down outside of a clinical setting, and finally just pick the brains of these amazing doctors to our heart's content!
Dr Einhorn will be Friday only, but Dr Pierorazio and Dr Cary aren't going anywhere! We're locking the doors, and looking forward to enlightening discussions for patients, survivors, and cancer advocates alike. This will also be an amazing opportunity for the doctors themselves to learn more about their patient populations and the advocacy world. We're looking forward to it!
Steve Pake
Co-Founder & Chair, Testicular Cancer Summit
Testicular Cancer Summit Keynote Speaker - Dr Phillip M. Pierorazio, M.D.
I am an urologist at Johns Hopkins in Baltimore, Maryland and a passionate advocate for our testicular cancer patients. I am a member of the National Comprehensive Cancer Network Guidelines Committee for Testicular Cancer and considered among the experts in robotic and open retroperitoneal lymph node dissection. There is no cancer like testicular cancer, it affects young men and because of the high cure rate, can have lasting effects for decades after successful treatment. For those reasons and more, there is no patient population like testicular cancer survivors – and there is no more rewarding group for whom to care.
I am an urologist at Johns Hopkins in Baltimore, Maryland and a passionate advocate for our testicular cancer patients. I am a member of the National Comprehensive Cancer Network Guidelines Committee for Testicular Cancer and considered among the experts in robotic and open retroperitoneal lymph node dissection. There is no cancer like testicular cancer, it affects young men and because of the high cure rate, can have lasting effects for decades after successful treatment. For those reasons and more, there is no patient population like testicular cancer survivors – and there is no more rewarding group for whom to care.
Thanks to giants in the field, like Dr. Einhorn, the overall cure rate for testicular cancer is 95%. However we still subject many men to side effects from chemotherapy, radiation therapy and surgery without completely understanding or imparting the long-term “toxicities” of these treatments. I, and others, think it’s time to stop patting ourselves on the back for curing 95% of men and start moving the bar higher to minimize the side effects of our treatments. While we are not willing to budge on the excellent cure rate, the newest generation of testicular cancer providers is keenly focused on improving the lives of our testicular cancer patients. I look forward to giving the medical perspective of Testicular Cancer Survivorship at the TC Summit and interacting with like-minded TC advocates from around the world!
Dr Phillip M. Pierorazio, M.D.
Assistant Professor of Urology and Oncology
Director, Division of Testis Cancer
Brady Urological Institute at Johns Hopkins University
Testicular Cancer Summit Keynote Speaker - Dr Ajay K. Nangia, MBBS
The Testicular Cancer Summit also pleased to welcome Dr Ajay K. Nangia, MBBS. Dr Nangia is a Professor of Urology at the University of Kansas Medical Center, and has expertise in the areas of male infertility and testosterone deficiency, of direct relevance to many testicular cancer survivors!
The Testicular Cancer Summit also pleased to welcome Dr Ajay K. Nangia, MBBS. Dr Nangia is a Professor of Urology at the University of Kansas Medical Center, and has expertise in the areas of male infertility and testosterone deficiency, of direct relevance to many testicular cancer survivors!
About Dr Nangia:
"Dr. Ajay K. Nangia is Professor of Urology at the University of Kansas Medical Center. Dr. Nangia received his medical degree from St. Thomas and Guy's Hospital Medical School in London, U.K. He completed two years of research at Yale University prior to residency. He completed his Urology residency at the University of Pittsburgh Medical Center and a Male Infertility and Microsurgery fellowship at the Cleveland Clinic Foundation in Cleveland, Ohio. Dr. Nangia was at Dartmouth-Hitchcock Medical Center in New Hampshire prior to coming to Kansas and the Kansas City area. Dr. Nangia is a fellowship trained male infertility specialist in the metropolitan Kansas City area with 14 years of experience and national involvement in the field. He is one of the leading male infertility specialists nationally and in Kansas, Missouri and the Midwest region. He has extensive experience in male infertility, urological microsurgical reconstruction, including vasectomy reversals in the Kansas, Western Missouri, Oklahoma and Nebraska region. He also specializes in Men's Health issues as they relate to sexual and reproductive health, especially male contraception, testosterone deficiency, erectile dysfunction and ejaculatory problems. He and Dr. Broghammer have one of the largest practices in surgical correction for erectile dysfunction (penile prostheses) in the region. He also specializes in fertility and sexual dysfunction issues related to spinal cord injuries and pre- and post-cancer treatment. Dr. Nangia is a leading national specialist in the field of vasectomies and complications from vasectomies. He also has a secondary specialty in stone disease. "
You can read Dr Nangia's full bio here.
We look forward to hearing from Dr Nangia at the Testicular Cancer Summit.
Testicular Cancer Summit Panelist - Emily Cox-Martin, PhD
The Testicular Cancer Summit is pleased to have Emily Cox-Martin, PhD as a panelist! "I am a Clinical Psychologist and Assistant Professor in the Division of Medical Oncology at the University of Colorado School of Medicine. Working in the field of Psycho-Oncology, I help patients improve coping and adjustment around their diagnosis. I focus on the difficulties that emerge at the intersection of cancer and mental health across the cancer continuum, from diagnosis into survivorship.
I am a Clinical Psychologist and Assistant Professor in the Division of Medical Oncology at the University of Colorado School of Medicine. Working in the field of Psycho-Oncology, I help patients improve coping and adjustment around their diagnosis. I focus on the difficulties that emerge at the intersection of cancer and mental health across the cancer continuum, from diagnosis into survivorship. Cancer is a disease that not only impacts our bodies, but our psychosocial functioning as well, including our mental health, our relationships, and how we take care of ourselves. At the Testicular Cancer Summit I hope to highlight that for cancer survivors, understanding and addressing the psychological impact of your disease is critical for your health, as well as your overall quality of life.
Emily Cox-Martin, PhD
Clinical Psychologist, Medical Oncology
University of Colorado Cancer Center - Anschutz
